Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
6,624.70
(
-1.36%
)
US TECH 100
23,755.20
(
-1.56%
)
Dow Jones
46,225.15
(
-1.63%
)
Brent Oil
108.63
(
1.92%
)
Bitcoin
71,146.50
(
-0.13%
)
News Focus
News Focus
Post# of 257257
Next 10
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

acgood

Send PM Follow Ignore
Followers 17
Posts 1093
Boards Moderated 0
Alias Born 05/12/2007

acgood

Re: DewDiligence post# 125934

Tuesday, 08/30/2011 10:08:06 PM

Tuesday, August 30, 2011 10:08:06 PM

Post# of 257257

Quote:
If MNTA were to ink a comprehensive FoB deal with PFE, do you see any chance of MNTA being able to carve out rights to partner a substitutable Enbrel FoB with another party?
No, I don’t see any chance of that.



I agree...and that is okay. there really isn't a prospective partner (exception being MRK of those mentioned) that doesn't have a program of their own vulnerable to potential FOB competition.

Did your list mostly cut off due to scale/resources? Any of the next tier or other foreign firms have a compelling "pro" rationale?

Any comments here may have previously been disseminated on Twitter @BioDueDiligence or at www.biotechduediligence.com

Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Trade Smarter with Thousands

Leverage decades of market experience shared openly.

Join Now